Type 2 Diabetes Studies
"Glycemia Reduction Approaches in Diabetes — A Comparative Effectiveness Type 2 Diabetes Study (GRADE)"
Purpose: To compare effectiveness of four commonly prescribed anti-diabetic medications to control blood sugar levels when combined with Metformin.
The GRADE study is for people:
People cannot be in the study if:
Other eligibility and exclusion criteria apply and will be reviewed at the time of screening.
Compensation: Eligible volunteers will receive diabetes care, metformin, assigned study medication and all necessary supplies without cost for up to 7 years.
"Clinical Protocol to Investigate the Efficacy of Amlexanox for Treatment of Glucose and Lipid Abnormalities in Obese Type 2 Diabetes"
Purpose: To find out how an investigational medicine, Amlexanox — formerly used for asthma and canker sores — can improve type 2 diabetes, insulin resistance, obesity, and non-alcoholic fatty liver disease (NAFLD). This is a translational study that is completely home-grown here at UM. Amlexanox is taken orally in a pill three times a day. We plan to continue therapy for a period of 12 weeks followed by a follow-up 4 weeks after therapy ends. We will evaluate the changes in metabolic parameters (e.g. blood cholesterol, liver function, insulin resistance) and body composition characteristics (e.g. the pattern of fat distribution in the body). Seven eligible subjects in this study will also be evaluated for a change in liver disease by a liver biopsy.
Compensation: $750 to $900
"EndoBarrier: A Novel Therapy for Type 2 Diabetes in Obese Adults"
Purpose: To evaluate the safety and initial efficacy of the EndoBarrier Gastrointestinal Liner System in uncontrolled Type 2 diabetic subjects who are also obese. The study will look to confirm whether the device can help control diabetes. UM has been selected as one of the 20 sites participating in a pivotal U.S. trial testing the novel device (the Endobarrier) as a new therapy for type 2 diabetes. Endobarrier is a duodenal sleeve that is about 2 feet long that gets placed into the duodenum and early part of the jejunum in the small intestine. The device may create at least part of the effects of gastric bypass surgery that allows the diabetes to go in remission. The device will be placed by Grace Elta, M.D., and Erik-Jan Wamsteker, M.D., of Gastroenterology Medicine at UM. Patients will be randomly assigned either to the actual device group or the “sham” operation group with a 2:1 ratio. The “sham” operation group will have a chance to receive the actual device after the first year of the study.
Compensation: $675 to $775
"Cardiovascular Outcomes Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients with a Recent Acute Coronary Syndrome (ACE) Event and Type 2 Diabetes Mellitus"
Exclusion list is long and includes:
All clinic visits are completed at Domino's Farms.
Compensation: All study related tests and procedures are free. Subjects receive a new glucose meter and glucose strips for the duration of the study.
"Epidemiology of Heterogeneity in Type 2 Diabetes"
Principal Investigator: Dr. Massimo T. Pietropaolo
Other eligibility factors:
Compensation: Compensation for completion of study varies, depending on extent of involvement in the study.
"Studying a Treament Improving Neuropathy in Type 2 Diabetes"
Principal Investigator: Dr. Rodica Pop-Busui
Other eligibility factors:
Compensation: $25.00 per visit
For general questions about our clinical studies, send email to firstname.lastname@example.org